BMC Pregnancy and Childbirth
BMC Pregnancy and Childbirth
BMC Pregnancy and Childbirth
BMC
2002,Pregnancy and Childbirth
2 x
Research article
Drug therapy and adverse drug reactions to terbutaline in obstetric
patients: a prospective cohort study in hospitalized women
Dulce Mara Hernndez-Hernndez*1, Mara Josefa E Vargas-Rivera2,
Alejandro A Nava-Ocampo2, Jos Antonio Palma-Aguirre2 and
Hctor Sumano-Lpez3
Address: 1Unit of Medical Research in Oncologic Diseases, Area de Epidemiologia, Hospital de Oncologa, Centro Medico Nacional "Siglo XXI",
Institute Mexicano del Seguro Social, Mexico City, Mexico, 2Unit of Medical Research in Pharmacology, Hospital de Especialidades, CMN "Siglo
XXI", IMSS, Mexico City, Mexico and 3Department of Pharmacology, Facultad de Medicina, Universidad Nacional Autnoma de Mxico, Mexico
City, Mexico
E-mail: Dulce Hernndez-Hernndez* - [email protected]; Mara Vargas-Rivera - [email protected]; Alejandro A Nava-
Ocampo - [email protected]; Jos Palma-Aguirre - [email protected]; Hctor Sumano-Lpez - [email protected]
*Corresponding author
Abstract
Background: Adverse drug reactions (ADR's) could be expected more frequently in pregnant
women. This study was performed in order to identify ADR's to tocolytic drugs in hospitalised
pregnant women.
Methods: A prospective cohort study was performed in two General Hospitals of the Instituto
Mexicano del Seguro Social (IMSS) in Mexico City. Two hundred and seven women undergoing labor,
premature labor, threatened abortion or suffering any obstetric related disease were included.
Drug prescription and signs and symptoms of any potential ADR were registered daily during the
hospital stay. Any potential ADR to tocolytic drugs was evaluated and classified by three of the
authors using the Kramer's algorithm.
Results: Of the 207 patients, an ADR was positively classified in 25 cases (12.1%, CI95% 8.1 to
17.5%). All ADR's were classified as minor reactions. Grouping patients with diagnosis of
threatened abortion, premature labor or under labor (n= 114), 24 ADR's were related to
terbutaline, accounting for a rate of 21.1 ADR's per 100 obstetric patients. Obstetric patients
suffering an ADR were older than obstetric patients without any ADR. However, the former
received less drugs/day patient-1 and had a shorter hospital stay (p < 0.05) whereas the dose of
terbutaline was similar between the two groups. Terbutaline inhibited uterine motility in women
with and without any ADR at a similar rate, 70 and 76% respectively (x2 = 0.07; p = 0.8).
Conclusion: Terbutaline, used as a tocolytic drug, was related to a high frequency of minor ADRs
and to a high rate of effcicacy.
Page 1 of 6
(page number not for citation purposes)
BMC Pregnancy and Childbirth 2002, 2 http://www.biomedcentral.com/1471-2393/2/3
Page 2 of 6
(page number not for citation purposes)
BMC Pregnancy and Childbirth 2002, 2 http://www.biomedcentral.com/1471-2393/2/3
Table 2: Characteristics of patients with diagnosis of threatened abortion, premature labor or labor in relation to the presence or not
of any ADR.
Page 3 of 6
(page number not for citation purposes)
BMC Pregnancy and Childbirth 2002, 2 http://www.biomedcentral.com/1471-2393/2/3
Discussion not an ADR. Although efficacy was not our goal, the uter-
Kramer et al., created an algorithm to identify and qualify ine inhibitor effects of terbutaline resulted in a high rate
any ADR without any drug assay [1214]. However, some of patients. The study was performed during a period of 4
problems have emerged with its use. It needs to be trans- months and we did not observe any patient re-entering
lated and adapted for using in different countries, as it into the hospital because of the presence of a new episode
happened to us. The algorithm is extensive, and therefore of uterine activity. Whether the patients underwent anoth-
time-consuming. It requires multiple specific information er period of uterine activity and received medical care in
that was collected due to the prospective nature of the another hospital or successfully completed the pregnancy
present study. Some data, however, could not be available period, cannot be clarified in our study. Also, the fetal and
in the clinical file for a retrospective evaluation. maternal long-term morbidity was unknown. Obstetri-
cian service is the main request of medical care in Mexican
Despite the Council of the International Organization of hospitals, and births have been 31.2% of total hospital
Medical Sciences has provided definitions and basic re- discharges, being 53.9% of total births registered in 1997
quirements for the proper use of ADR terminology [19], a attended at the IMSS [9]. A careful selection of pregnant
diagnosis is often difficult to establish due to the presence women in order to avoid a dangerous impact to both or
of clinical conditions or prescription of two or more either the mother and the fetus due to the production of
drugs. Casuality assessment for ADR's is therefore often palpitations counterbalancing the benefits between its use
difficult in the clinical setting [20]. Comparisons among for managing a threatened abortion or a premature labor
the reported ADR's frequencies are also problematic due and costs of minor ADR's, must be mandatory. Further-
to the differences observed among the studies, including more, the small range of current options to be used as to-
the population (e.g. pediatric, adults or old patients), gen- colytics should stimulate this area in order to identify
der, set of the study (e.g. emergency rooms or hospitalized drugs with lesser production of side effects. In fact, terbu-
patients), and method of measurement (e.g. therapeutic taline could not only be undangerous for the fetus but to
drug monitoring, spontaneous reports) [4,10,11,2128] . promote neonatal respiration and metabolic adaptation
The frequency of 12.1% of ADR's reported in the current after elective cesarean section and to reduce the number of
study was lower than the 33.3% reported for all admis- fetal heart abnormalities [33,34].
sions at an Indian hospital [29], and than 28.2% reported
at a Universitary hospital [11]. However, it resulted higher In relation to indomethacin, this drug has proved safety
than 2.4 to 3.7% of ADR's observed in other studies for and efficacy to inhibit uterine contractions of premature
hospitalized patients [4,10]. Differences could be ex- labor [35,36]. Uterine contractility at term and preterm re-
plained by the fact that obstetric patients do receive a less- sults from an activation of myometrium through several
er amount or less agressive theraphy than patients process varying from mechanical stimulation to a com-
attended e.g. at internal medical wards. plex cascade of endocrine processes [37]. Prostaglandinds
are important regulators of the labor process [38], and
We studied women patients requiring hospital attention therefore its manipulation has resulted into a direct effect
for non-accidental causes, and despite a high incidence of favoring or inhibiting uterine activity [39,40]. However, it
ADR's was identified in patients receiving terbutaline for is well known the adverse effects of all nonsteroidal anti-
premature labor and threatened abortion, mortality was inflamatory drugs administered at the third trimester of
not present. Terbutaline is worldwide formerly approved pregnancy [4143], including constriction of the ductus
for the treatment of asthma. As it was recently reviewed by arteriosus, persistent fetal circulation, impairment of renal
Lam et al. [30], in the United States the off-label utility of function and bleeding. Furthermore, brain maldevelop-
terbutaline as a tocolytic agent has been known by clini- ment and neurobehaviour deviations have been experi-
cians for more than 20 years, estimating that at least mentally demonstrated after neonatal exposure to
260,000 women are yearly receiving terbutaline during indomethacin [44]. Therefore, despite our results seem
pregnancy, being the most popular prescribed -mimetic likely to favour indomethacin administration because it
for tocolysis in the USA. In Mexico, it is also extensively was better tolerated than terbutaline for tocolysis, the se-
used in the obstetric wards provably favored by the fact rious adverse effects potentially produced in the fetus by
that other therapuetic options as ritodrine did never arrive indomethacin make this drug a greatly dangerous option
to our country. In fact, ritodrine was removed from the for preterm labor management.
marked in the United States [30].
Additionally, incidence of preterm birth is greatly in-
Terbutaline is clearly an effective inhibitor of uterine activ- creased among the socially disadvantaged women, proba-
ity [31,32], and its ADR's are abated with discontinuing bly explained by two major factors [45]. First, the presence
treatment only. In our study, no differences in dose of of chronic and acute social stressors which in turn are
terbutaline were detected between patients suffering or translated into organc responses. Second, the presence of
Page 4 of 6
(page number not for citation purposes)
BMC Pregnancy and Childbirth 2002, 2 http://www.biomedcentral.com/1471-2393/2/3
a gene-environment interaction based on a highly preva- 11. Caranasos GJ, Stewart RB, Cluff LE: Drug-induced illness leading
to hospitalization. JAMA 1974, 228:713-717
lence mutation in the gene for methylentetrahydrofolate 12. Kramer MS, Leventhal JM, Hutchinson TA, Feinstein AR: An algo-
reductase. Even more, maternal education level could de- rithm for the operational assessment of adverse drug reac-
crease infant mortality rate by preventing preterm births tions. I. Background, description, and instructions for use.
JAMA 1979, 242:623-632
[46], without affecting fetal growth [47]. In the present 13. Hutchinson TA, Leventhal JM, Kramer MS, Karch FE, Lipman AG,
study, most patients have the basic education level, and Feinstein AR: An algorithm for the operational assessment of
therefore if any effect was present this would be protector. adverse drug reactions. II. Demonstration of reproducibility
and validity. JAMA 1979, 242:633-638
Finally, there is a need for a simple, efficient and low-cost 14. Leventhal JM, Hutchinson TA, Kramer MS, Feinstein AR: An algo-
of ADR's reporting system covering a wide range of the rithm for the operational assessment of adverse drug reac-
tions. III. Results of tests among clinicians. JAMA 1979,
population receiving any drug. The spontaneous reports 242:1991-1994
probably satisfy these conditions and participation of 15. Vargas-Rivera J, Hernndez HDM, Sumano LH, Palma AA, Bondani
nurses in the design of strategies of recognizing any ADR GA, Ponce MH: Reacciones adversas a los medicamentos en
pacientes peditricos en dos hospitales de segundo nivel. Rev
is undoubtedly necessary [48,49]. Med IMSS 1996, 34:421-427
16. Elwood MJ: Critical appraisal od epidemiological studies and
clinical trials. New York, Oxford University Press 1998, 104-108
In conclusion, terbutaline was responsible of a high rate 17. Landis JR, Koch GG: The measurement of observer agreement
of mild ADR's in women receiving this drug as a tocolytic for categorical data. Biometrics 1977, 33:159-174
agent. However, the lack of well recognized options 18. Capell D, Laporte JR: Spontaneous notification of adverse drug
reactions (in Spanish). In: Phncipios de epidemiologa de los medica-
makes terbutaline the major tocolytic drug currently avail- mentos 1993, 147-170
able. 19. Venulet J, Bankowski Z: Harmonising adverse drug reaction ter-
minology: the role of the Council for International Organiza-
tions of Medical Sciences. Drug Saf 1998, 19:165-172
Competing interests 20. Meyboom RH, Hekster YA, Egberts AC, Gribnau FW, Edwards IR:
None declared Causal or casual? The role of causality assessment in phar-
macovigilance. Drug Saf 1997, 17:374-389
21. Mariani L, Minora T, Ventresca GP: Drug surveillance and ad-
Acknowledgements verse reactions to drugs. The literature and importance of
All the authors dedicate the paper to the memory of the Pharmacist Mara historical data (in Italian). Clin Ter 1996, 147:653-672
Josefa E. Vargas-Rivera "Pepita", who devoted the last years of her wonder- 22. Mariani L: Pharmacovigilance: education and continuing up-
ful existency to promote the studies of pharmacovigilance at the IMSS. In dating. The role of university institutes (in Italian). Clin Ter
fact, the present study was proposed by her and it could not be completed 1998, 149:219-225
without her participation. Dr. A. A. Nava-Ocampo thanks the grant re- 23. Thurmann PA, Schmitt K: Detection and evaluation of adverse
ceived, as a member, from the Sistema Nacional de Investigadores. The drug effects (in German). Med Klin 2000, 95:4-8
helpful and patient assistance of Mr. Victor Manuel Vzquez for preparing 24. Martin RM, Biswas PN, Freemantle SN, Pearce GL, Mann RD: Age
the manuscript in English language is also thanked. Support in any form was and sex distribution of suspected adverse drug reactions to
not received from any pharmaceutical company. newly marketed drugs in general practice in England: analy-
sis of 48 cohort studies. Br J Clin Pharmacol 1998, 46:505-511
25. Ciorciaro C, Hartmann K, Kuhn M: Differences in the relative in-
References cidence of adverse drug reactions in relation to age? An eval-
1. Olsson S: The role of the WHO program on International uation of the spontaneous reporting system of SANZ (Swiss
Drug Monitoring in coordinating wolrdwide drug safety ef- Drug Monitoring Center) (in German). Schweiz Med Wochenschr
forts. Drug Saf 1998, 19:1-10 1998, 128:254-258
2. Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse drug re- 26. Muoz MJ, Ayani I, Rodriguez-Sasiain JM, Gutirrez G, Aguirre C: Ad-
actions in hospitalized patients: a meta-analysis of prospec- verse drug reaction surveillance in pediatric and adult pa-
tive studies. JAMA 1998, 279:1200-1205 tients in an emergency room (in Spanish). Med Clin (Barc) 1998,
3. Detournay B, Fagnani F, Ouyanne P, Haramburu F, Begaud B, Welsch 111:92-98
M, Imbs JL: Cost of hospitalizations related to side-effects 27. Tran C, Knowles SR, Liu BA, Shear NH: Gender differences in ad-
drugs (in French). Thrapie 2000, 55:137-139 verse drug reactions. J Clin Pharmacol 1998, 38:1003-1009
4. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP: Adverse 28. Classen DC, Pestotnik SL, Evans RS, Burke JP: Computerized sur-
drug events in hospitalized patients. Excess lenght of stay, veillance of adverse drug events in hospital patients. JAMA
extra costs, aand attributable mortality. JAMA 1997, 277:301- 1991, 266:2847-2851
306 29. Uppal R, Jhaj R, Malhotra S: Adverse drug reactions among inpa-
5. Walson PD: Therapeutic drug monitoring in special popula- tients in a north Indian referral hospital. Natl Med J India 2000,
tions. Clin Chem 1998, 44:415-419 13:16-18
6. Ghandour FZ, Knauss TC, Hricik DE: Immunosuppressive drugs 30. Lam F, Elliott J, Jones JS, Katz M, Knuppel RA, Morrison J, Newman R,
in pregnancy. Adv Ren Replace Ther 1998, 5:31-37 Phelan J, Willcourt R: Clinical issues surrounding the use of
7. Becerril-Martnez MC, Daz-Martnez A, Bondani-Guasti A: Intro- terbutaline sulfate for preterm labor. Obstet Gynecol Surv 1998,
duccin a la farmacovigilancia. Mxico DF, Secretara de Salud, 53(suppl):S85-S95
1995, 13-14 31. Perry KG Jr, Morrison JC, Rust OA, Sullivan CA, Martin RW, Naef
8. Instituto Nacional de Estadstica, Geografa e Informtica: XII Censo RW 3rd: Incidence of adverse cardiopulmonary effects with
General de Poblacin y Vivienda 2000: Sntesis de Resulta- low-dose continuous terbutaline infusion. Am J Obstet Gynecol
dos. IAEGI: Estados Unidos Mexicanos [http://www.inegi.gob.mx] 1995, 173:1273-1277
9. Secretara de Salud, Direccin General de Estadstica e Informtica 32. Gyetvai K, Hannah ME, Hodnett ED, Ohisson A: Tocolytics for pre-
del Sistema Nacional de Salud, Sistema Sectorial de Informacin en term labor: a systematic review. Obstet Gynecol 1999, 94:869-
Salud: Principales servicios de hospitalizacin por institucin 877
de salud. Bol Inform Estad 1997, 1:25-43 33. Kulier R, Hofmeyr GJ: Tocolytics for suspected intrapartum fe-
10. Brennan TA, Leape LL, Laird NM, Hebert L, Localio AR, Lawthers tal distress. Cochrane Database Syst Rev 2000, 2:CD000035
AG, Newhouse JP, Weiler PC, Hiatt HH: Incidence of adverse 34. Eisler G, Hjertberg R, Lagercrantz H: Randomised controlled trial
events and negligence in hospitalized patients. Results of the of effect of terbutaline before elective caesarean section on
Harvard Medical Practice Study I. N Eng J Med 1991, 324:370-
376
Page 5 of 6
(page number not for citation purposes)
BMC Pregnancy and Childbirth 2002, 2 http://www.biomedcentral.com/1471-2393/2/3
Pre-publication history
The pre-publication history for this paper can be accessed
here:
Page 6 of 6
(page number not for citation purposes)